Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 11, 2024, covers events occurring on that date, including the 2024 Annual Meeting of Stockholders held in San Diego, California, and a change in Board composition. The record date for the meeting was April 15, 2024, with 46,523,185 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel matters rather than financial performance.
Material Changes
- Board Departure: Gary Pace notified the Board of his intent to retire, effective June 30, 2024. The departure is not due to any disagreement with the Company.
- Consulting Arrangement: Dr. Pace will enter into a one-year consulting agreement (July 1, 2024, to June 30, 2025) for $3,200 per quarter for up to eight hours of work.
- Annual Meeting Results: Stockholders approved the election of four Class I directors, the ratification of KPMG LLP as the independent auditor, and the advisory vote on executive compensation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific compensation arrangement for the retiring director.
Investor Verification Checklist
- Verify the terms of the fifth amendment to the consulting agreement with Dr. Pace in the upcoming Form 10-Q.
- Confirm the final composition of the Board of Directors following Dr. Pace's retirement on June 30, 2024.
- Review the detailed voting breakdown for the executive compensation advisory vote (Proposal 3), which received 4,087,635 "Against" votes.